Cutaneous Small/Medium CD4+ Pleomorphic T-Cell Lymphoma–Like Nodule in a Patient With Erythema Chronicum Migrans
Abstract: CD4+ small/medium pleomorphic T-cell lymphoma is a relatively rare subtype of cutaneous lymphoproliferative disorder with an indolent clinical behavior. The place of this condition among lymphomas is debatable. The authors describe a rare case of the direct association of CD4 small/medium pleomorphic T-cell lymphoma–like solitary nodule with Borrelia burgdorferi infection in a 5-year-old boy, discuss the reactive nature of this condition, and emphasize the importance of clinicopathological correlation.
Authors: Lee JY, Kim HJ, Kwon E, Choi JY, Oh HJ, Kim JS PMID: 33029984 [PubMed]
Authors: Morimoto A, Fujioka Y, Ushiku T, Kurokawa M PMID: 33028779 [PubMed - as supplied by publisher]
We report the rare case of a patient co-existing NS and DLBCL. DLBCL might be pathogenesis of NS; the findings are supported by the presence of MN, an underlying malignancy (DLBCL), and the lack of anti-PLA2R antibodies. Although further investigation is warranted, our case suggests that DLBCL is a possible cause of secondary MN. PMID: 33028760 [PubMed - in process]
Authors: Cáceres-Perkins W, Cabanillas F, San Vicente G, Rivera-Franceschini C, Sobrino-Najul E, Vega-Vázquez LI, Conde-Sterling D Abstract Mucosa-associated lymphoid tissue (MALT) lymphomas are B-cell neoplasms that commonly affect the gastrointestinal (GI) tract, usually the stomach. In most cases, extranodal marginal zone lymphoma (ENMZL) is an indolent disease. Bone marrow involvement is common with MALT lymphoma accompanied by paraproteinemia; such involvement impels disease progression. Here, we present the case of an 82-year-old Hispanic patient with long-standing ENMZL in whom the gastric site...
CONCLUSION: Our data suggest that these two polymorphisms do not contribute to AD in the population from the Mersin region of the Eastern Mediterranean. Further studies with larger sample sizes must be conducted to ascertain the association between the 2 polymorphisms. PMID: 33031695 [PubMed - as supplied by publisher]
Conclusion: Pola + BR is cost-effective versus BR for the treatment of transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma in the US. PMID: 33028076 [PubMed - as supplied by publisher]
No abstract available
Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hajime Yasuda, Yutaka Tsukune, Tadaaki Inano, Yosuke Mori, Yasunori Ota, Norio Komatsu
Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Andrew Tiu, Vinicius Jorge, Peter Moussa, Djeneba Audrey Djibo, Sorab Gupta, Onder Alpdogan, Claudia Dourado
Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ryujiro Hara, Makoto Onizuka, Sawako Shiraiwa, Kaito Harada, Yasuyuki Aoyama, Daisuke Ogiya, Masako Toyosaki, Rikio Suzuki, Sinichiro Machida, Ken Ohmachi, Yoshiaki Ogawa, Hiroshi Kawada, Shigeki Watanabe, Akira Miyajima, Ryota Masuda, Masayuki Iwazaki, Mikio Mikami, Takashi Koike, Hiroyuki Mochizuki, Kiyoshi Ando